Orchestra BioMed Holdings Inc Ordinary Shares OBIO 深 沪
已收盘 10-17 16:00:00 美东时间
3.32
-0.360
-9.78%
华盛通- 最 高3.69
- 今 开3.60
- 成交量 33.38万股
- 最 低 3.26
- 昨 收 3.68
- 总市值 1.79亿
- 52周最高 6.50
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 2.20
- 委 比 93.75%
- 总股本 5395.51万
- 历史最高 23.39
- 量 比 0.53
- 振 幅 11.68%
- 历史最低 2.20
- 每 手 1
- 风险率 1.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE:MDT) have a strategic
10-09 20:06
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
Orchestra BioMed will present AVIM Therapy clinical evidence, highlighting its potential to halt hypertensive heart disease, at the Georgia Innovation Summit. The therapy has FDA Breakthrough Device Designation and is being developed with Medtronic for uncontrolled hypertension in pacemaker-indicated patients, targeting over 750,000 globally. Pilot studies show significant blood pressure reduction, cardiac function improvement, and lasting effect...
10-09 12:00
OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation
Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025 | Fellow Shareholders: Recent clinical announcements related to our AVIM therapy
09-22 22:10
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
Orchestra BioMed announced that AVIM therapy, a new treatment for uncontrolled hypertension, demonstrated sustained blood pressure reduction, reversibility, and reproducibility in long-term follow-up. Key findings include a 3.6-year follow-up showing a 8.9 mmHg reduction in systolic blood pressure, no rebound hypertension upon deactivation, and immediate restoration of effects upon reactivation. The therapy has FDA Breakthrough Device Designation...
09-04 21:00
Theriva Biologics Has Received A Notice Of Allowance For A U.S. Patent Titled "ALKALINE PHOSPHATASE FORMULATIONS (FOR THE TREATMENT OF MICROBIOME-RELATED DISEASES)".
https://patentcenter.uspto.gov/applications/18744950/ifw/docs
09-04 03:58
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Orchestra BioMed announced positive data from a pressure-volume loop study showing AVIM therapy effectively reduces systolic blood pressure and improves cardiovascular hemodynamics in pacemaker-indicated patients with uncontrolled hypertension. The therapy demonstrated significant reductions in blood pressure, cardiac workload, and intra-cardiac volumes without adverse effects on stroke volume. Published in JACC: Clinical Electrophysiology, the s...
08-26 11:30
BTIG Downgrades Orchestra BioMed Hldgs to Neutral
BTIG analyst Marie Thibault downgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Buy to Neutral.
08-20 19:20
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
AvIM Therapy Shows Promise in Treating Hypertension and Diastolic Dysfunction. MODERATO II study demonstrates significant reductions in systolic blood pressure and improvements in cardiac function in patients with hypertension and diastolic dysfunction, a key contributor to heart failure with preserved ejection fraction (HFpEF). The study highlights the potential of AVIM therapy to address unmet medical needs in managing hypertensive heart diseas...
08-14 12:00
Orchestra BioMed Hldgs Q2 EPS $(0.50) Beats $(0.51) Estimate, Sales $836.000K Beat $695.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.51) by 0.99 percent. This is a 11.11 percent decrease over losses of $(0.45) per share
08-12 20:17
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Orchestra BioMed announced Q2 2025 financial results, including $111.2 million in gross proceeds from strategic transactions and equity offerings, FDA regulatory milestones for AVIM therapy and Virtue SAB, expanded BACKBEAT study enrollment, and a $101 million cash position.
08-12 12:14
